Company

SRTD Biotech GmbH

SRTD Biotech develops selectively expressed RNA therapies for diseases including liver cancer and glioblastoma.

About

Founded in 2023, SRTD Biotech develops selectively expressed RNA therapies intended to target diseased cells in conditions including primary liver cancer and glioblastoma. Its seRNA approach is being studied in preclinical research, including animal models. The company is based in Julich, Germany, and was founded by Dr. Bernd Hoffmann (CEO) and Dr. Heribert Bohlen. In November 2024, it raised an undisclosed amount in seed funding led by High-Tech Gründerfonds.

1Funding rounds

1Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in